Aurobindo Pharma tumbles 4% as subsidiary receives a warning letter from USFDA

Aurobindo further said, the company will be engaging with the regulator and are fully committed to resolving this issue at the earliest.

from India Infoline News Service https://ift.tt/37pq7Lc